KALA BIO, Inc. (KALA) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US4831193010

Price
0.16 USD
Market cap
3.11 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

KALA BIO, Inc. financials

Fiscal year2025
Revenue0.00 USD
Operating income-39.16 m USD
EBIT-24.84 m USD
Net income-26.98 m USD
Diluted EPS – continuing operations-3.31 USD

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About KALA BIO, Inc.

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.